E-MAIL UPDATES

Click here to join
our Electronic Communications.

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Announces United States Patent Grant for IMP701 Antibody

July 15th 2020
press releases

Immutep Completes Recruitment for Part A Of Phase II TACTI-002 Study

June 29th 2020
press releases

Immutep Receives A$1,437,826 R&D Tax Incentive

June 22nd 2020
press releases
more

Investor updates

Investor updates.

Investor Update - November 2019

November 22nd 2019
investor updates

Investor Update - January 2019

January 31st 2019
investor updates

Investor Update - June 2018

June 19th 2018
investor updates
more

Analyst reports

Analyst reports.

goetzpartners securities - ASCO data underscores efti-PD-1 / L1 synergy

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

June 3rd 2020
analyst reports

Bell Potter - ASCO data further builds case for efti+Keytruda, with HNSCC looking more attractive (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

June 3rd 2020
analyst reports

JonesTrading - Responses to Efti + Pembro are Deepening Over Time, as is the Combo’s Market Opportunity with ASCO Data Positing Promise in New Indications

June 2nd 2020
analyst reports
more